Table 1.
Baseline characteristics of enrolled patients.
| Characteristics | Total (n=269) | Training cohort (n=149) | Validation cohort (n=120) | P value |
|---|---|---|---|---|
| Age (years), Mean± SD | 59.6 ± 9.7 | 59.5 ± 8.9 | 59.7 ± 10.6 | 0.888 |
| Gender (Male/Female) | 167/96 | 95/51 | 72/45 | 0.555 |
| BMI (≥24 kg/m2/<24 kg/m2) | 85/178 | 51/95 | 34/83 | 0.312 |
| Location (Head/Body and tail) | 162/101 | 88/58 | 74/43 | 0.622 |
| Tumor size (≥4cm/<4cm) | 77/186 | 44/102 | 33/84 | 0.732 |
| Jaundice (Yes/No) | 88/175 | 44/102 | 44/73 | 0.202 |
| Hypertension (Yes/No) | 49/214 | 23/123 | 26/91 | 0.181 |
| Diabetes (Yes/No) | 62/201 | 32/114 | 30/87 | 0.480 |
| AJCC 8th TNM stage (I/II/III) | 131/124/8 | 73/69/4 | 58/55/4 | 0.950 |
| Hemoglobin (g/L), Median (IQR) | 133(122-142) | 133(123-141) | 133(119-144) | 0.658 |
| White blood cell (109/L), Median (IQR) | 5.49(4.57-6.89) | 5.59(4.63-7.30) | 5.46(4.50-6.52) | 0.278 |
| Blood platelet (109/L), Median (IQR) | 215(181-271) | 210(179-258) | 222(182-284) | 0.341 |
| Neutrophil (109/L), Median (IQR) | 3.41(2.64-4.51) | 3.38(2.52-4.69) | 3.42(2.68-4.31) | 0.740 |
| Lymphocyte (109/L), Median (IQR) | 1.40(1.08-1.75) | 1.43(1.05-1.82) | 1.34(1.10-1.71) | 0.606 |
| Total cholesterol (mmoI/L), Median (IQR) | 4.71(3.87-5.22) | 4.63(3.92-5.26) | 4.76(3.81-5.19) | 0.962 |
| Pre-albumin (mg/dL), Mean± SD | 19.8 ± 5.9 | 20.0 ± 5.8 | 19.5 ± 6.0 | 0.428 |
| Albumin (g/L), Median (IQR) | 42.8(39.9-44.8) | 42.9(40.8-45.0) | 42.3(39.1-44.8) | 0.446 |
| Fibrinogen (g/L), Median (IQR) | 3.43(3.02-3.98) | 3.41(3.04-3.96) | 3.46(2.94-4.15) | 0.781 |
| CA199 (≥37U/ml/<37U/ml) | 190/73 | 101/45 | 89/28 | 0.215 |
| CEA (≥5ng/ml/<5ng/ml) | 84/179 | 46/100 | 38/79 | 0.867 |
| CA125(≥35U/ml/<35U/ml) | 49/214 | 30/116 | 19/98 | 0.372 |
| Lymph node metastasis (Yes/No) | 77/186 | 40/106 | 37/80 | 0.454 |
| Laparoscopic surgery (Yes/No) | 65/198 | 38/108 | 27/90 | 0.581 |
| PTCD (Yes/No) | 31/232 | 18/128 | 13/104 | 0.761 |
IQR, interquartile range; BMI, body mass index; AJCC, American Joint Committee on Cancer; TNM, tumor node metastasis; SD, standard deviation; CA, carbohydrate antigen; CEA, carcinoembryonic antigen; PTCD, percutaneous transhepaticcholangial drainage.